Patenting Nature: What Ruling in Myriad Case Means for Biotechnology and DNA Diagnostics
| dc.contributor.author | Cook-Deegan, Robert Mullan | |
| dc.date.accessioned | 2013-07-16T15:21:12Z | |
| dc.date.available | 2013-07-16T15:21:12Z | |
| dc.date.issued | 2011-08-11 | |
| dc.description | Editorial in 'The Cancer Letter', written by Professor Robert Cook-Deegan. This article was included in background materials provided at the September, 2011 Congressional briefing. | |
| dc.identifier.uri | ||
| dc.language.iso | en_US | |
| dc.subject | Genetics, Myriad Genetics, ACLU, BRCA, Breast Cancer, Amicus Brief, Gene Patents, Law, Health Policy, Medicine, Women’s Health | |
| dc.title | Patenting Nature: What Ruling in Myriad Case Means for Biotechnology and DNA Diagnostics | |
| dc.type | Other |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- BCD Cancer Letter 8.11 for 9.11 Congressional Briefing.pdf
- Size:
- 280.6 KB
- Format:
- Adobe Portable Document Format
- Description:
- Robert Cook-Deegan editorial in 'The Cancer Letter'